Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL)

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.13
Views: 3947
Rating:

Dr Richard Furman - New York Weill Cornell Medical Center, USA

Dr Furman talks to ecancertv at ASH 2013 about his study: "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)"

Idelalisib (IDELA) is a first-in-class, selective, oral inhibitor of PI3Kδ that reduces proliferation, enhances apoptosis, and inhibits homing and retention of malignant B cells in lymphoid tissues.

This Phase 3 study evaluated the efficacy and safety of Idelalisib plus rituximab vs placebo plus retuximab in patients with previously treated CLL.

Idelalisib plus rituximab demonstrated statistically significant improvement with acceptable safety over placebo plus rituximab in PFS, ORR, LNR and OS in heavily pretreated patients with relapsed CLL, including those with adverse genetic features.

 

Related videos

follow us

ONJ e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation